Key Points
-
Tilray has been aggressively pursuing acquisitions in recent years.
-
Its focus has largely been on loading up on craft brewers in the U.S. market.
-
The company hasn’t been as eager to expand in Canada, and recently announced it was consolidating some of its operations there.
-
Aurora Cannabis (NASDAQ:ACB) has been a surprisingly hot stock of late. Its value has been on the rise as both Curaleaf Holdings and Organigram Global have made offers for its business. Aurora has been encouraging investors to reject Curaleaf’s takeover attempt and to instead agree to a friendly deal the company recently reached with Organigram.
What may be surprising, however, is that Tilray Brands (NASDAQ:TLRY), which has been hungry for growth and no stranger to acquisitions in recent years, didn’t make a bid or appear interested. Here’s why I think it didn’t bother with a move that could have grown its market share in both Canada and international cannabis markets.
Missed AI’s “Act 1”? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But according to our analysts, we’re only at the end of “Act 1″—the R&D phase. “Act 2” is the global rollout. Continue »
Image source: Getty Images.
Tilray’s focus appears to be on the U.S. market
In recent years, Tilray has been in acquisition mode, but there are a couple of things to note about its recent moves. The first is that the Canadian-based cannabis company has mainly been acquiring beverage companies, and the second is that many of them operate in the U.S. market, as it has now become one of the largest craft brewing companies in the country.
I believe it’s doing this for a couple of reasons. In addition to growing sales, it appears eager to build a presence in the U.S. market however it can. Beverages are a logical way to diversify its operations, and in the future, it could transform those facilities should it need to. Plus, cannabis-infused beverages are one of the fastest-growing areas of the entire marijuana industry, so there is some potential overlap there.
Meanwhile, investing in a Canadian producer such as Aurora in a market where competition is intense may simply not be all that enticing for Tilray. Recently, the company announced it was consolidating some of its operations in an effort to focus on profitability. Acquiring one of the larger cannabis companies in Canada may simply not make sense given its long-term strategy.
Is Tilray’s stock worth taking a chance on?
Aurora’s stock is up this year due to multiple acquisition attempts for its business. Otherwise, it might be on a trajectory similar to Tilray’s stock, which is down more than 70% this year.
It’s been a downright horrendous year for Tilray. While investors may be tempted to take a position in the company because, if the U.S. moves forward with legalization in the future, the stock could take off, it’s a highly risky position.
A better move may be to simply take a wait-and-see approach and put the stock on a watch list. If legalization takes place in the U.S., there will be plenty of upside for Tilray; there’s no need to rush to buy the stock today, when there’s still nothing on the horizon.
Should you buy stock in Tilray Brands right now?
Before you buy stock in Tilray Brands, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tilray Brands wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 16, 2026.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Organigram Global. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.